Gerilimzumab: Phase I data

A pair of double-blind, placebo-controlled Phase I trials in a total of 50 healthy volunteers showed that single doses of 1, 5, 15 and 30 mg subcutaneous gerilimzumab and once-monthly 5 and 20 mg dose...